Aamund regrets overly-ambitious strategy in Neurosearch
Had Neurosearch had two to three drugs for rare diseases, the biopharmaceutical corporation would have been a self-sustaining, profitable company today. That is the message delivered by Asger Aamund, who regrets that Neurosearch went exclusively after major drugs. Now he will focus on the development of niche medicine in Bavarian Nordic
af LEONORA BECK
From the outset, Neurosearch reached for the stars. The aim was drugs for widespread diseases such as cancer, depression and Alzheimer’s, but that strategy should have included another branch – niche medicine, admits Asger Aamund, who is co-founder and former chairman of the board in Neurosearch.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
